Editorial: Cyclic Nucleotide Phosphodiesterases (PDEs) Signaling in the Endocrine System

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2025 Feb 13

PMID 39944203

Authors

Federica Campolo

Arun Samidurai

Affiliations

Soon will be listed here.

References

Huang W, Sundquist J, Sundquist K, Ji J . Phosphodiesterase-5 inhibitors use and risk for mortality and metastases among male patients with colorectal cancer. Nat Commun. 2020; 11(1):3191. PMC: 7314744. DOI: 10.1038/s41467-020-17028-4. View

Di Luigi L, Corinaldesi C, Colletti M, Scolletta S, Antinozzi C, Vannelli G . Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy. Inflammation. 2016; 39(3):1238-52. PMC: 4883282. DOI: 10.1007/s10753-016-0359-6. View

De Joussineau C, Sahut-Barnola I, Levy I, Saloustros E, Val P, Stratakis C . The cAMP pathway and the control of adrenocortical development and growth. Mol Cell Endocrinol. 2011; 351(1):28-36. PMC: 3678347. DOI: 10.1016/j.mce.2011.10.006. View

Conti M . Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol Endocrinol. 2000; 14(9):1317-27. DOI: 10.1210/mend.14.9.0534. View

Samidurai A, Xi L, Das A, Iness A, Vigneshwar N, Li P . Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities. Pharmacol Ther. 2021; 226:107858. PMC: 8815087. DOI: 10.1016/j.pharmthera.2021.107858. View

Kurtz A, Gotz K, Hamann M, Wagner C . Stimulation of renin secretion by nitric oxide is mediated by phosphodiesterase 3. Proc Natl Acad Sci U S A. 1998; 95(8):4743-7. PMC: 22561. DOI: 10.1073/pnas.95.8.4743. View

Dremier S, Milenkovic M, Blancquaert S, Dumont J, Doskeland S, Maenhaut C . Cyclic adenosine 3',5'-monophosphate (cAMP)-dependent protein kinases, but not exchange proteins directly activated by cAMP (Epac), mediate thyrotropin/cAMP-dependent regulation of thyroid cells. Endocrinology. 2007; 148(10):4612-22. DOI: 10.1210/en.2007-0540. View

Aumo L, Rusten M, Mellgren G, Bakke M, Lewis A . Functional roles of protein kinase A (PKA) and exchange protein directly activated by 3',5'-cyclic adenosine 5'-monophosphate (cAMP) 2 (EPAC2) in cAMP-mediated actions in adrenocortical cells. Endocrinology. 2010; 151(5):2151-61. DOI: 10.1210/en.2009-1139. View

Liu N, Mei L, Fan X, Tang C, Ji X, Hu X . Phosphodiesterase 5/protein kinase G signal governs stemness of prostate cancer stem cells through Hippo pathway. Cancer Lett. 2016; 378(1):38-50. DOI: 10.1016/j.canlet.2016.05.010. View

10.

Zaccolo M, Movsesian M . cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007; 100(11):1569-78. DOI: 10.1161/CIRCRESAHA.106.144501. View

11.

Lavoie J, Sigmund C . Minireview: overview of the renin-angiotensin system--an endocrine and paracrine system. Endocrinology. 2003; 144(6):2179-83. DOI: 10.1210/en.2003-0150. View

12.

Campolo F, Pofi R, Venneri M, Isidori A . Priming metabolism with the type 5 phosphodiesterase: the role of cGMP-hydrolyzing enzymes. Curr Opin Pharmacol. 2021; 60:298-305. DOI: 10.1016/j.coph.2021.08.007. View

13.

Pullamsetti S, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J . Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Sci Transl Med. 2017; 9(416). DOI: 10.1126/scitranslmed.aai9048. View

14.

Catalano S, Campana A, Giordano C, Gyorffy B, Tarallo R, Rinaldi A . Expression and Function of Phosphodiesterase Type 5 in Human Breast Cancer Cell Lines and Tissues: Implications for Targeted Therapy. Clin Cancer Res. 2015; 22(9):2271-82. DOI: 10.1158/1078-0432.CCR-15-1900. View

15.

Cesarini V, Martini M, Vitiani L, Gravina G, Di Agostino S, Graziani G . Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. Oncotarget. 2017; 8(8):13223-13239. PMC: 5355091. DOI: 10.18632/oncotarget.14656. View

16.

Gresser U, Gleiter C . Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. Eur J Med Res. 2002; 7(10):435-46. View

17.

Szarek E, Stratakis C . Phosphodiesterases and adrenal Cushing in mice and humans. Horm Metab Res. 2014; 46(12):863-8. PMC: 4730987. DOI: 10.1055/s-0034-1389916. View

18.

Muniyan S, Rachagani S, Parte S, Halder S, Seshacharyulu P, Kshirsagar P . Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling. Clin Cancer Res. 2020; 26(21):5720-5734. PMC: 7642013. DOI: 10.1158/1078-0432.CCR-20-1569. View

19.

Samidurai A, Xi L, Das A, Kukreja R . Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. Annu Rev Pharmacol Toxicol. 2022; 63:585-615. DOI: 10.1146/annurev-pharmtox-040122-034745. View

20.

Beavo J . Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995; 75(4):725-48. DOI: 10.1152/physrev.1995.75.4.725. View